Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

House Health Bill To Include Public Plan, Insurers Resisting
On Monday, House Ways and Means Committee Chairman Charles Rangel, D- N.Y., told reporters that the House bill will include a new public insurance plan, Reuters/The Boston Globe reports. "Similar to legislation being developed in the Senate, the House bill would establish an insurance exchange to help people without employer-sponsored insurance find medical coverage." The government-sponsored public insurance plan would be "one of the options available, lawmakers said." The bill would also establish a mandate that would "require individuals and businesses to obtain coverage."

Cancer Therapeutics, Inc.'s Partner NanoTherapies, Inc. Utilizes Revolutionary Solution For Disrupting And Treating Cancer
Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced its new partner, NanoTherapies, Inc., is utilizing calcium phosphate nanoparticles to detect and treat cancer. These particles are about 350 times smaller than a human cell while providing both a safe and effective way to transport drugs and imaging materials into diseased cells.
News of the day
Gates Foundation Donates Additional $80M To Indian HIV-Prevention Program, Receives Indira Gandhi Prize For Peace, Disarmament And Development
The Bill & Melinda Gates Foundation will give an additional $80 million to Avahan, a foundation initiative launched in 2003 for HIV prevention programs in India, Bill Gates said on Thursday, the Seattle Times blog, "Business of Giving" reports. Previous foundation commitments to the program, "which involves more than 100 non-profits in six Indian states," total $258 million, the blog writes (Heim, 7/23).
Diagnostics

Independent Study Confirms Superior Properties Of ZPC(TM) Enhanced Calcium Composite Bone Grafts

A recent independent study has confirmed Fortoss Vital(R), developed by the Pioneering Orthobiologics Company, Biocomposites, as an effective bone replacement material demonstrating superior bone regenerative properties due to its unique negative zeta potential control (ZPC(TM)). The research carried out by the hospital and departments of the university of Aachen and the Universities of Munich and Regensburg, Germany, analysed the osteogenic potential of Fortoss Vital for maxillary sinus floor augmentation on a 61 year old female. The samples taken from the graft site at 6 months, showed the negative surface charge of Fortoss Vital had accelerated the bone formation cascade and rapidly produced mature lamellar bone formation with marrow cavities. The bone density at the graft site was shown to be denser than the original bone matrix of the posterior maxillary region. Evidence also confirmed the complete resorption of Fortoss Vital. Fortoss Vital is a unique, bi-phasic calcium composite bone graft material having a negative surface charge which attracts the key proteins and cells for rapid osteogenesis and bone repair. Fortoss Vital is fully resorbed by osteoclastic processes and replaced by bone. Biocomposites" Managing Director Stephen Bratt said, "This independent clinical data in a maxillofacial indication, corroborates similar orthopaedic studies confirming that Biocomposites" ZPC technology, with a unique surface chemistry accelerates bone growth. About the company: Biocomposites is a privately held, leading developer, manufacturer and distributor of synthetic, tissue regeneration products. Since 1997, the company has developed a broad range of products that addresses the clinical and economic needs of medical specialties in orthopaedics and dentistry. Research, manufacturing, sales and marketing are directed from the company"s headquarters in Keele, Staffordshire, UK. Biocomposites also has two subsidiary companies, based in Shanghai, P.R.China and Wilmington, North Carolina, USA. Fortoss Vital(R) and Biocomposites(R) The Next Regeneration(TM) are registered trademarks of Biocomposites Ltd. Referenes: Smeets et al. " A new biphasic osteoinductive calcium composite material with a negative Zeta potential for bone augmentation." Head & face Medicine 2009, 5:13 doi:10.1186/1746-160X-5-13. Biocomposites Ltd


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009